Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
Pacira BioSciences Inc (NASDAQ: PCRX) closed the day trading at $23.62 down -1.05% from the previous closing price of $23.87. In other words, the price has decreased by -$1.05 from its previous closing price. On the day, 0.57 million shares were traded. PCRX stock price reached its highest trading level at $24.0 during the session, while it also had its lowest trading level at $23.47.
Ratios:
For a better understanding of PCRX, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.38 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 9.07. For the most recent quarter (mrq), Quick Ratio is recorded 1.91 and its Current Ratio is at 2.38. In the meantime, Its Debt-to-Equity ratio is 0.83 whereas as Long-Term Debt/Eq ratio is at 0.55.
On January 30, 2025, Truist Upgraded its rating to Hold which previously was Sell and also upped its target price recommendation from $8 to $25.
Truist Downgraded its Buy to Sell on August 13, 2024, whereas the target price for the stock was revised from $30 to $8.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 04 ’25 when Ceesay Abraham sold 2,354 shares for $27.19 per share. The transaction valued at 64,005 led to the insider holds 9,039 shares of the business.
Ceesay Abraham bought 2,354 shares of PCRX for $64,005 on Sep 04 ’25. On Aug 07 ’25, another insider, BIGAL MARCELO, who serves as the Director of the company, sold 4,912 shares for $23.67 each. As a result, the insider received 116,267 and left with 11,393 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PCRX now has a Market Capitalization of 1072544064 and an Enterprise Value of 1246849920. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.50 while its Price-to-Book (P/B) ratio in mrq is 1.40. Its current Enterprise Value per Revenue stands at 1.766 whereas that against EBITDA is 7.87.
Stock Price History:
The Beta on a monthly basis for PCRX is 0.37, which has changed by 0.51604617 over the last 52 weeks, in comparison to a change of 0.15927899 over the same period for the S&P500. Over the past 52 weeks, PCRX has reached a high of $27.64, while it has fallen to a 52-week low of $15.16. The 50-Day Moving Average of the stock is -6.46%, while the 200-Day Moving Average is calculated to be -2.94%.
Shares Statistics:
Over the past 3-months, PCRX traded about 645.90K shares per day on average, while over the past 10 days, PCRX traded about 478390 shares per day. A total of 44.90M shares are outstanding, with a floating share count of 43.70M. Insiders hold about 2.74% of the company’s shares, while institutions hold 116.01% stake in the company. Shares short for PCRX as of 1757894400 were 6685410 with a Short Ratio of 10.35, compared to 1755216000 on 6288411. Therefore, it implies a Short% of Shares Outstanding of 6685410 and a Short% of Float of 21.34.
Earnings Estimates
As of right now, 6.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $0.86, with high estimates of $0.94 and low estimates of $0.8.
Analysts are recommending an EPS of between $2.97 and $2.78 for the fiscal current year, implying an average EPS of $2.87. EPS for the following year is $3.26, with 6.0 analysts recommending between $3.52 and $2.82.
Revenue Estimates
6 analysts predict $182.86M in revenue for. The current quarter. It ranges from a high estimate of $187.3M to a low estimate of $179.13M. As of. The current estimate, Pacira BioSciences Inc’s year-ago sales were $168.57MFor the next quarter, 6 analysts are estimating revenue of $204.93M. There is a high estimate of $209.9M for the next quarter, whereas the lowest estimate is $201.13M.
A total of 6 analysts have provided revenue estimates for PCRX’s current fiscal year. The highest revenue estimate was $743.5M, while the lowest revenue estimate was $731.33M, resulting in an average revenue estimate of $737.83M. In the same quarter a year ago, actual revenue was $700.97MBased on 6 analysts’ estimates, the company’s revenue will be $812.06M in the next fiscal year. The high estimate is $829.6M and the low estimate is $785.2M.
